Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 09:24 AM
November 2025
In this session from the GHAPP MASLD Community Network, supported by Madrigal Pharmaceuticals, hepatology expert HoChong Gilles, DNP, from the Richmond VA Medical Center, explores the evolving understanding of MetALD (Metabolic dysfunction-associated Alcohol-related Liver Disease). Through a detailed case study, Gilles examines how metabolic risk factors and alcohol intake intersect to drive fibrosis progression, highlighting diagnostic tools such as FibroScan, biomarkers like PEth, and key distinctions between MASLD, MASH, and alcohol-predominant liver disease. This presentation underscores the importance of assessing true alcohol exposure, utilizing noninvasive testing, and integrating lifestyle interventions for improved liver and metabolic outcomes.
Related Webcast
Webcast: MASLD Basics With Punam Punja
October 2025
Punam Punja, PA provides an overview of MASLD basics, explaining the 2023 terminology update that replaced NAFLD/NASH with MASLD/MASH and introduced MetALD for patients with metabolic dysfunction and alcohol exposure. Learn how to diagnose MASLD using imaging, metabolic risk factors, and non-invasive tests such as FIB-4, ELF, and FibroScan—plus when to refer for hepatology evaluation or liver biopsy. Punja also reviews staging, HCC surveillance, and practical lifestyle recommendations for patients at risk of fibrosis and cirrhosis.
Watch Now
Webcast: MASLD Basics With Edith Johannes
November 2025
Learn the fundamentals of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in this educational session featuring Edith Johannes, NP, a liver specialist at UCLA Health with over 17 years of experience in hepatology and liver transplantation. Supported by the GHAPP MASLD Community Network and Madrigal Pharmaceuticals, this session explores the new terminology and diagnostic criteria for MASLD—formerly known as NAFLD and NASH—and explains why these changes matter for both clinicians and patients. Viewers will gain a clear understanding of how to evaluate patients presenting with hepatic steatosis, distinguish MASLD from alcohol- or drug-induced liver injury, and apply key diagnostic tools such as FIB-4, ELF testing, and elastography to assess fibrosis progression. Johannes also discusses the clinical importance of ruling out overlapping conditions, recognizing metabolic risk factors, and identifying patients at risk for fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Whether you’re new to hepatology or seeking a concise refresher, this talk provides a practical framework for diagnosing and managing MASLD in primary and specialty care.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Erin Parkinson
July 2025
In this in-depth clinical discussion, Erin Parkinson, NP from the Tampa General Medical Group Transplant Institute, walks through the nuanced process of differentiating stage 3 and stage 4 fibrosis in patients with MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease). Using two illustrative case studies, she explores key clinical signs, lab values, and non-invasive staging tools such as FibroScan, FIB-4, ELF score, and MR elastography. Parkinson discusses the importance of early identification of advanced fibrosis, the reversibility of stage 3 disease, and the implications of a diagnosis of cirrhosis. Erin outlines evidence-based treatment pathways including lifestyle interventions, use of GLP-1 receptor agonists, and initiation of resmetirom (Rezdiffra) for stage 2–3 fibrosis. For cirrhotic patients, the focus shifts to HCC surveillance, screening for clinically significant portal hypertension, and consideration of non-selective beta blockers like carvedilol. This video offers practical insights for hepatology providers navigating the evolving MASLD landscape and highlights how early intervention and accurate staging can impact long-term outcomes.
Watch Now
Webcast: MASLD vs MetALD With Alison Moe
November 2025
In this insightful session, Alison Moe, PA-C, from Atlantic Gastroenterology Associates, a division of United Digestive, breaks down how to distinguish metabolic-associated steatotic liver disease (MASLD) from MetALD—the overlap of metabolic dysfunction and alcohol-related liver injury. Using a real-world case study, Alison highlights how small amounts of daily alcohol intake can significantly accelerate fibrosis in patients with metabolic risk factors like PCOS, hypertension, and dyslipidemia. She explains how to interpret FibroScan (kPa/CAP) results, evaluate PEth testing for alcohol exposure, and determine when therapies such as Resmetirom are appropriate. This discussion emphasizes practical strategies for counseling patients on alcohol cessation, lifestyle modification, and fibrosis monitoring, helping clinicians better identify and manage those at risk for advanced liver disease.
Watch Now
Webcast: MASLD Basics With Scott Springer
August 2025
Welcome to the GHAPP MASLD Community Network, where Scott Springer, PA-C, from Erie County Medical Center in Buffalo, NY, provides a comprehensive overview of the evolving landscape of steatotic liver disease. Sponsored by Madrigal Pharmaceuticals, this session breaks down the recent nomenclature shift from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Scott explores how overlapping etiologies like alcohol-associated liver disease (ALD) and the emerging classification of MetALD better reflect real-world patient populations. Learn about key diagnostic strategies—including the use of FIB-4, ELF score, and transient elastography—to assess fibrosis risk and guide referral to hepatology care. With a clinical case study, Scott highlights the importance of accurate staging, ruling out alternative etiologies, and understanding progression rates in high-risk patients. This session is a must-watch for GI and hepatology APPs looking to stay updated on guidelines, non-invasive diagnostics, and best practices for managing MASLD/MASH in primary and specialty settings.
Watch Now
Webcast: MASLD Pharmacotherapy With April Morris
August 2025
Join April Morris, NP, a hepatology and endocrinology nurse practitioner, for a comprehensive review of MASLD pharmacotherapy as part of the GHAPP MASLD Community Network. This expert-led session outlines a three-pronged strategy for managing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH, focusing on obesity reduction, cardiometabolic risk control, and liver-directed treatment. April walks through first-line lifestyle approaches, highlights key pharmacologic agents like GLP-1 receptor agonists, and explains their mechanisms and clinical relevance—including the groundbreaking data from the semaglutide trials showing resolution of MASH and improvement in liver fibrosis. The session also reviews the role and limitations of vitamin E and pioglitazone, emphasizing their risks in patients with diabetes or cardiovascular disease. The spotlight then shifts to resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist FDA-approved for adults with non-cirrhotic NASH and moderate-to-advanced fibrosis (F2–F3). April explains the MAESTRO-NASH trial endpoints, clinical efficacy, common side effects, and appropriate patient selection. Learn how resmetirom improves fatty acid oxidation, reduces hepatic fat and fibrosis, and the key drug–drug interactions and statin dose considerations to manage during treatment. The discussion concludes with practical tips for monitoring, non-invasive staging (FibroScan, ELF, MRI-PDFF), and the evolving guidance on treatment duration, safety labs, and insurance barriers. This session is essential for clinicians navigating the growing landscape of therapeutic options in MASLD/MASH care.
Watch Now
Webcast: MASLD Pharmacotherapy With Christina Hanson
September 2025
Learn about the latest advances in MASLD and MASH pharmacotherapy in this educational session from the GHAPP MASLD Community Network. Christina Hanson, NP, reviews the evolving landscape of treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), including the critical role of weight loss, cardiovascular risk reduction, and liver-directed therapies. The discussion covers current management strategies such as GLP-1 receptor agonists, bariatric interventions, statins, and lifestyle modification, while also exploring guideline-supported options like vitamin E and pioglitazone. Special attention is given to the first FDA-approved therapy for MASH, Resmetirom, including its mechanism, clinical trial results, safety considerations, and monitoring recommendations. Whether you are a hepatology specialist, primary care provider, endocrinologist, or advanced practice provider, this session highlights practical approaches to managing patients with MASLD and MASH and offers insights into emerging therapies that may shape future clinical practice.
Watch Now
Webcast: MASLD Basics With Chantil Jeffreys
September 2025
In this MASLD/MASH Community Network “Basics” session, Chantil Jeffreys, FNP clarifies the new MASLD/MASH nomenclature, how to recognize metabolic criteria (obesity, dyslipidemia, hypertension, impaired glucose/A1C, low HDL), and when to rule out other causes (alcohol overlap, DILI, cryptogenic disease). She walks through a practical primary-care workflow: start with FIB-4, then risk-stratify with FibroScan or ELF, identify patients who need hepatology referral, and decide when liver biopsy is appropriate (discordant/indeterminate NITs, suspected concomitant disease, select older patients). The talk covers global prevalence, natural history and progression (F0→F4/cirrhosis→HCC), and why aggressive cardiometabolic risk reduction and appropriate surveillance matter. You’ll leave with a clear algorithm to stage disease, monitor over time, and communicate the MASLD/MASH shift to colleagues and patients.
Watch Now
Webcast: Non-Invasive Testing With Brian Lam
August 2025
Join Brian Lam, PA-C, Associate Medical Director of Research at Inova’s Liver and Obesity Research Program and Chair of the Global NASH/MASH Council’s PA Committee, for a masterclass on non-invasive testing (NITs) in the evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH, presented through the GHAPP MASLD/MASH Community Network and sponsored by Madrigal Pharmaceuticals. In this dynamic and case-based session, Brian outlines a practical, step-by-step approach to identifying patients at risk for advanced fibrosis, using tools like FIB-4, ELF, FibroScan (VCTE), and MR Elastography. He walks through the critical cutoffs, diagnostic performance, limitations, and how to interpret imaging and lab-based scores in real-world hepatology and primary care settings. You'll learn how to apply AGA and AASLD clinical algorithms, the importance of staging patients with diabetes and metabolic syndrome, and how to distinguish low-risk MASLD from at-risk MASH. Brian also shares best practices for TE reliability, quality control, and using NIT combinations like FAST, MAST, and MEFIB for accurate diagnosis. With clear visuals, expert insights, and actionable takeaways, this session is an essential update for APPs, GI, hepatology, and primary care providers managing fatty liver disease in 2025 and beyond.
Watch Now
Webcast: MASLD Basics With Ann Moore
September 2025
In this episode of MASLD Basics, Ann Moore, NP with Arizona Liver Health, explains the new terminology and approach to what was once called fatty liver disease. She breaks down how “NAFLD” is being replaced with steatotic liver disease and how patients are now categorized based on underlying drivers such as metabolic dysfunction, alcohol use, or other conditions. Ann highlights why MASLD and MASH are the most common and important to recognize, what risk factors providers should look for, and why early detection matters. She also discusses how primary care teams can use simple non-invasive tests, lifestyle changes, and new treatment options to identify at-risk patients before fibrosis and cirrhosis develop. This talk is designed to give APPs, clinicians, and healthcare providers a clear, practical overview of the evolving landscape of liver disease care.
Watch Now